Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
Enterotoxigenic Escherichia (E.) coli (ETEC) bacteria are the main cause of traveler's
 diarrhea and are significant pathogens affecting children and elderly individuals of
 developing countries. The purpose of the study is to determine the safety of the ETEC-Cholera
 vaccine and the body's ability to protect itself against ETEC and cholera infection after
 receiving the vaccine. The study will enroll a total of 64 healthy volunteers, 18 to 45 years
 old at the Cincinnati Children's Hospital. The study will provide increasing doses of the
 vaccine or placebo (inactive substance) to 4 groups consisting of 16 participants each.
 Participants will remain in the inpatient unit for observation for about 11 days. All
 subjects will be treated with Cipro, an antibiotic, for 5 days. Study procedures include:
 blood samples, vital signs, physical examinations, and stool samples. Volunteers will be
 involved in the study for about 8 months including telephone contacts.
Enterotoxigenic Escherichia coli (ETEC) are the principal single cause of traveler's diarrhea
 and are a significant pathogen affecting children and elderly individuals of developing
 countries. ETEC infections result in approximately 600 million total cases of diarrhea
 worldwide annually, with an estimated 280 million cases and over 400,000 deaths in children
 less than 5 years of age. The proposed study is a randomized, double-blind, placebo
 controlled, dose-escalation, inpatient Phase I study to determine the safety and
 immunogenicity of a single oral dose of a combined live, attenuated, enterotoxigenic
 Escherichia coli (ETEC)-cholera vaccine (Peru-15 pCTB). A total of 64 healthy subjects, 18 to
 45 years old will be enrolled in this study. Subject participation duration is up to 8
 months. Sequential cohorts of 16 eligible subjects will be randomized in a 3:1 ratio to
 receive the assigned dose of ETEC-cholera vaccine or placebo (bicarbonate buffer only),
 respectively. The first dose level cohort (1x10^7 colony forming units) will be divided into
 2 groups. Initially, 4 subjects will be enrolled, treated, and observed to ensure the
 tolerability of this dose level through Day 28. In the absence of any stopping rules,
 enrollment and dosing will proceed with the remaining 12 subjects of this cohort. Thereafter,
 dose escalation and subject enrollment will proceed in a step-wise fashion. A Safety
 Monitoring Committee will be convened for this study, and will review available safety data
 through the Day 28 post-vaccination visits for each cohort prior to making a recommendation
 to the Sponsor on advancement to the next dose level. The study will be conducted at
 Cincinnati Children's Hospital. The primary objective of this study will be to assess the
 safety of a combined ETEC-cholera vaccine [Peru-15-pCTB (Cholera toxin B-subunit)] when
 administered as a single oral dose over a range of doses in healthy adult subjects compared
 to placebo at day 28 post-vaccination. The secondary objectives will be: to assess long-term
 safety follow-up from immunization through Month 6 post vaccination; to evaluate the
 immunogenicity of a single oral dose of ETEC-cholera vaccine over a range of doses in healthy
 adult subjects; and to evaluate the shedding profile of the ETEC-cholera vaccine organisms in
 stool for a period of 7 days.
Inclusion Criteria:

 -  Male or female age 18-45, inclusive.

 -  Healthy as judged by the Principal Investigator (PI) and determined by medical
 history, physical examination, vital signs, screening laboratories, and medication
 history.

 -  Capable of understanding, consenting and complying with the entire study protocol
 including the inpatient period.

 -  Female subjects must be of non-childbearing potential, or if of childbearing potential
 (as determined by the investigator) must be practicing abstinence or using an
 effective licensed method of birth control (e.g., oral contraceptives; diaphragm or
 condom in combination with contraceptive jelly, cream, or foam; intrauterine
 contraceptive device, or Depo-Provera; skin patch; vaginal ring or cervical cap) for
 30 days prior to vaccination and must agree to continue such precautions during the
 study and for 30 days after the Day 28 study visit.

 -  Male subjects must agree not to father a child during the study and for 90 days after
 the Day 0 study visit.

 -  Provide voluntary written informed consent and attained at least 70% on an examination
 about the study on the first attempt.

 -  Have normal screening laboratories for serum glutamic pyruvic transaminase (SGPT)
 alanine aminotransferase (ALT), creatinine, sodium, potassium, total white blood count
 (WBC), hemoglobin, neutrophils, lymphocytes, platelets, urine protein, urine glucose
 and urine red blood cells (RBC).

 Exclusion Criteria:

 -  Women who are pregnant or lactating or have a positive serum pregnancy test at
 screening or upon admission to inpatient facility.

 -  Subjects who are immunocompromised or immunodeficient, or have had a prior malignancy
 (exception: a history of basal cell or squamous cell carcinoma in remission without
 treatment for more than 5 years prior to study entry).

 -  History of clinically significant chronic illness or other condition requiring chronic
 medication therapy.

 -  History of malabsorption or maldigestion disorder (e.g., celiac sprue), major
 gastrointestinal (GI) surgery, or any other chronic GI disorders that would interfere
 with the study or the investigational product.

 -  Any current or past use of immunosuppressive medications including inhaled steroids
 (e.g., for asthma) within 6 months of screening.

 -  Recent (e.g., within 5 years) history of travel to a cholera or Enterotoxigenic
 Escherichia coli (ETEC) endemic area, raised in a cholera or ETEC endemic area or a
 history of raising a child from an endemic area for cholera or ETEC. Individuals who
 may work with Vibrio (V) cholerae or ETEC in the laboratory are also excluded.

 -  Vaccination against or infection with cholera or E. coli, or participation in a
 clinical trial using cholera or ETEC vaccine or organisms at any time.

 -  History of drug or alcohol abuse any time in the last 6 months.

 -  Presence of HIV antibody, hepatitis C antibody, or positive hepatitis B surface
 antigen.

 -  Clinically abnormal screening electrocardiogram (ECG) defined as pathologic Q waves
 and significant ST-T wave changes; criteria for left ventricular hypertrophy; and any
 non-sinus rhythm excluding isolated premature atrial contractions.

 -  Presence of bacterial or parasitic pathogens in stool culture in a screening stool
 examination.

 -  IgA (immunoglobulin) deficiency.

 -  A change in subject's normal stool pattern within 3 months of screening visit. A
 normal stool pattern is defined as 3 to 21 stools per week.

 -  Any known allergy or sensitivity to Ciprofloxacin.

 -  Have any known allergy to components of the vaccine [M9 minimal salts, glycerin,
 dextrose anhydrous, sodium chloride, peptone (vegetable) acid hydrolysate, magnesium
 sulfate heptahydrate, and aspartame] or placebo/bicarbonate buffer (water, sodium
 bicarbonate, ascorbic acid, and aspartame).

 -  Any medical illness requiring a new prescription medication or hospitalization during
 the screening period or having a temperature greater than or equal to 38.0 degrees
 Celsius during the 2 weeks prior to investigational product administration (Day 0).

 -  Administration of any vaccine, licensed or investigational, or any investigational
 product within 30 days of investigational product administration (Day 0) or any plan
 for participation in another investigational trial during this study.

 -  Use of antibiotics within 7 days of investigational product administration (Day 0).

 -  Use of laxatives for hard or infrequent stools one or more times in a month in any of
 the 3 months prior to enrollment.

 -  Use of any H2 receptor antagonists (e.g., Tagamet®, Zantac®, and Pepcid®), proton pump
 inhibitors (e.g., Prilosec® over the counter (OTC), Protonix®, and Prevacid®), or
 prescription acid suppression medication or OTC antacids within 72 hours of
 investigational product administration.

 -  Use of prescription and OTC medications that contain acetaminophen, aspirin,
 ibuprofen, and other nonsteroidal anti-inflammatory drugs within 48 hours prior to
 investigational product administration.

 -  Employment as a commercial food handler, day care worker, or health care worker
 involved in direct patient contact. Subjects with children less than 2 years old at
 home or with household contacts that are immunocompromised, pregnant or
 breast-feeding.

 -  Any other condition or responsibility, such as a medical, psychiatric, or social
 condition or occupational responsibility that, in the judgment of the investigator,
 would interfere with or serve as a contraindication to the subject's participation in
 the protocol or assessment of the investigational product.

 -  Subjects who are unwilling or unable to cease smoking for the duration of the
 inpatient stay.

 -  Subjects who are unable to pass a test that describes cholera and ETEC diarrhea and
 explains the requirements of the clinical trial. Subjects must score a minimum of 70
 percent upon the first attempt.

 -  Subjects will be excluded if their screening laboratory test results fall outside of
 the laboratory normal; however, transaminase levels [alanine aminotransferase (ALT)]
 and creatinine levels (Cr) below the lower limit of "normal" will not be an exclusion
 criterion.

 -  Subjects with Phenylketonuria (PKU) will be excluded because the investigational
 product (vaccine) bicarbonate buffer contains aspartame.